Treatment of Multiple Myeloma: Thalidomide-, Bortezomib-, and Lenalidomide-Induced Peripheral Neuropathy

Publisher： Karger

E-ISSN： 2296-5262|37|9|506-513

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.37, Iss.9, 2014-08, pp. : 506-513

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib-Induced Rhabdomyolysis in Multiple Myeloma

By  

Acta Haematologica, Vol. 116, Iss. 3, 2006-10 ,pp. : 203-206

Karger

Access to resources Recommend Favorite

Bortezomib‐thalidomide‐dexamethasone versus bortezomib‐cyclophosphamide‐dexamethasone as induction therapy prior to autologous stem cell transplantation in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 4, 2015-02 ,pp. : 605-606

John Wiley & Sons Inc

Access to resources Recommend Favorite

Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients

By  

Acta Haematologica, Vol. 129, Iss. 1, 2012-10 ,pp. : 35-39

Karger

Access to resources Recommend Favorite

Lenalidomide-Induced Hypersensitivity Pneumonitis

By  

Oncology Research and Treatment, Vol. 33, Iss. 5, 2010-04 ,pp. : 219-219

Karger

Access to resources Recommend Favorite

Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple Myeloma

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 25-31

Karger

Access to resources Recommend Favorite